PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCarglumic acid
Carbaglu(carglumic acid)
Carbaglu, Carglumic Acid, Ucedane (carglumic acid) is a small molecule pharmaceutical. Carglumic acid was first approved as Carbaglu on 2003-01-24. It is used to treat hyperammonemia in the USA. It has been approved in Europe to treat hyperammonemia, inborn errors amino acid metabolism, and propionic acidemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Carbaglu, Carglumic acid
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carglumic acid
Tradename
Company
Number
Date
Products
CARBAGLURecordatiN-022562 RX2010-03-18
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
carbagluNew Drug Application2024-01-25
carglumic acidANDA2024-03-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hyperammonemia—D022124E72.20
Agency Specific
FDA
EMA
Expiration
Code
CARGLUMIC ACID, CARBAGLU, RECORDATI RARE
2028-01-22ODE-345
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AA: Amino acids and derivatives
— A16AA05: Carglumic acid
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AcidosisD000138EFO_1000014E87.2————22
Propionic acidemiaD056693—E71.121————22
Inborn errors amino acid metabolismD000592——————11
HyperammonemiaD022124—E72.20————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCarglumic acid
INNcarglumic acid
Description
Carglumic acid is a urea that is the N-carbamoyl derivative of L-glutamic acid. An orphan drug used to treat a deficiency in the enzyme N-acetylglutamate synthase, which leads to acute hyperammonaemia. It has a role as an orphan drug and a carbamylphosphate synthetase I activator. It is a N-acyl-L-glutamic acid and a member of ureas.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NC(=O)N[C@@H](CCC(=O)O)C(=O)O
Identifiers
PDB—
CAS-ID1188-38-1
RxCUI—
ChEMBL IDCHEMBL1201780
ChEBI ID71028
PubChem CID121396
DrugBankDB06775
UNII ID5L0HB4V1EW (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 339 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
715 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use